Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iovance Biotherapeutics IncfiledCriticalIovance Biotherapeutics Inc
Publication of AR119647A1publicationCriticalpatent/AR119647A1/en
La presente da a conocer métodos mejorados y/o abreviados para expandir TIL y producir poblaciones terapéuticas de TIL, incluyendo métodos para expandir poblaciones de TIL en un sistema cerrado que lleva a una eficacia mejorada, fenotipo mejorado y salud metabólica incrementada de los TIL en un período de tiempo más corto, dando lugar a la vez a una contaminación microbiana reducida y a costos reducidos. Los métodos pueden comprender realizar la edición genética de por lo menos una porción de los TIL para potenciar su eficacia terapéutica. Esos TIL son de utilidad en regímenes de tratamiento terapéuticos.Hereby discloses improved and/or abbreviated methods for expanding TILs and producing therapeutic populations of TILs, including methods for expanding populations of TILs in a closed system leading to improved efficacy, improved phenotype, and increased metabolic health of TILs in a shorter period of time, resulting in both reduced microbial contamination and reduced costs. The methods may comprise gene editing at least a portion of the TILs to enhance their therapeutic efficacy. Those TILs are useful in therapeutic treatment regimens.
ARP190101109A2018-04-272019-04-26
GEN EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY
AR119647A1
(en)
Targeting T Cell Bioenergetics By Modulating P-Glycoprotein Selectively Depletes Alloreactive T Cells to Prevent Graft-Versus-Host Disease While Maintaining Antitumor Immunity
Effectiveness of internal use mineral diluted water well№ 3-k nynivske field in restorative treatment of patients with non-alcoholic fatty liver disease